Citizens Jmp Reiterates Market Outperform Rating for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “market outperform” rating reissued by Citizens Jmp in a research report issued on Tuesday,Benzinga reports. They presently have a $86.00 price target on the stock. Citizens Jmp’s target price indicates a potential upside of 51.17% from the company’s previous close.

CRSP has been the subject of several other research reports. Zacks Research upgraded shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Needham & Company LLC cut their price target on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating for the company in a report on Monday, November 10th. Royal Bank Of Canada raised their price objective on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 11th. Citigroup reiterated a “buy” rating and set a $77.00 target price (down previously from $87.00) on shares of CRISPR Therapeutics in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, October 8th. Twelve research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $68.35.

CRISPR Therapeutics Trading Up 0.8%

NASDAQ:CRSP opened at $56.89 on Tuesday. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $78.48. The stock’s 50 day simple moving average is $57.80 and its 200-day simple moving average is $57.07. The firm has a market cap of $5.42 billion, a P/E ratio of -10.18 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million. Research analysts forecast that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares in the company, valued at $17,262,789.91. This represents a 16.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 56,213 shares of company stock worth $3,810,458 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors have recently bought and sold shares of CRSP. Mirae Asset Global Investments Co. Ltd. increased its position in shares of CRISPR Therapeutics by 5.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after buying an additional 180 shares in the last quarter. IFP Advisors Inc boosted its position in shares of CRISPR Therapeutics by 24.6% in the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after buying an additional 181 shares in the last quarter. Cerity Partners LLC grew its stake in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after acquiring an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp increased its holdings in CRISPR Therapeutics by 3.0% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock valued at $339,000 after acquiring an additional 200 shares in the last quarter. Finally, Optiver Holding B.V. increased its holdings in CRISPR Therapeutics by 71.4% during the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after acquiring an additional 210 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Early zugo‑cel clinical data showed sustained B‑cell depletion and early efficacy across autoimmune and cancer studies, which traders read as a strong validation of CRSP’s pipeline and lifted the stock. How Early Zugo‑cel Data and Lilly Partnership Could Impact CRISPR Therapeutics CRSP Stock Rises on Encouraging Early Data From Zugo‑cel Studies
• Positive Sentiment: Analyst support strengthened the tape: Citizens/JMP reiterated a market‑outperform and Needham reaffirmed a buy, both with high price targets (mid‑$80s to $80), giving implied upside vs. current levels. Citizens Reiterates Market Outperform Analyst Price Target Coverage
• Positive Sentiment: Technical momentum: CRSP cleared a key benchmark and reached an 80+ relative‑strength rating, a signal some momentum traders use to add exposure. RS Rating Coverage
• Neutral Sentiment: Longer‑term thesis debate: a Fool.com piece questions whether CRISPR is “yesterday’s news,” noting the stock’s fall from prior highs and highlighting the challenge of scaling commercial execution after early approvals. This is more thematic commentary than immediate catalyst. Is CRISPR Therapeutics Stock Yesterday’s News?
• Neutral Sentiment: Short‑interest report appears erroneous or inconclusive (entries show “0 shares” and NaN increases); there’s no clear short‑squeeze signal from the published data. Investors should treat this item with caution.
• Negative Sentiment: Market‑wide weakness pressured the stock in the prior session — a Zacks note flagged a ~2.5% intraday decline, indicating CRSP is still sensitive to broader biotech/market flows despite company‑specific positives. CRSP Stock Falls Amid Market Uptick

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.